Rina Wu DeCamillis
Vice President, Sakura Bioscience
With experience in leading product development and operations management, Dr. DeCamillis joined Sakura Finetek as Senior Director of Advanced Staining Development in January 2016 through the Genemed acquisition, where she was Vice President of R&D and Operations.
Dr. DeCamillis brings over 20 years of experience in development of in-vitro diagnostic (IVD) medical devices, especially in antibody characterization by immunohistochemistry (IHC), DNA probe development and their application in chromogenic/fluorescence in situ hybridization (CISH/FISH) within various biotech organizations including Zymed Laboratories, Inc., Invitrogen Corporation, and Genemed Biotechnologies, Inc. She has led a team that developed and commercialized more than 150 biomarkers and detection systems for Sakura Finetek’s Tissue-Tek Genie® Advanced Staining platform to date.
Dr. DeCamillis has numerous scientific publications and a patent on CISH. She was a R&D Lead for the initial PMA submission of the Zymed Laboratories/Invitrogen SPOT-Light® HER2 CISH Kit to the FDA. Dr. DeCamillis completed her medical residency in the First Hospital at Beijing University in their Department of Pediatrics in 1989, and earned her Ph.D. in Human Genetic and Molecular Biology in 1995 at Catholic University of Leuven, Belgium. She completed a postdoctoral fellowship in the Department of Neuroscience and Neurology at Albert Einstein College of Medicine in New York in 1999.
Dr. DeCamillis was promoted to Vice President, Sakura Bioscience Operations in May 2020 and her responsibilities expanded to include both reagent R&D and manufacturing operations.